Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
32.47 USD | -3.56% | +3.08% | +5.49% |
May. 13 | Collegium Pharmaceutical Launches $35 Million Accelerated Share Repurchase Program | MT |
May. 10 | Needham Downgrades Collegium Pharmaceutical to Hold From Buy | MT |
Chart calendar Collegium Pharmaceutical, Inc.
Upcoming events on Collegium Pharmaceutical, Inc.
Past events on Collegium Pharmaceutical, Inc.
2024-05-16 08:30 am | Annual General Meeting |
2024-05-09 04:30 pm | Q1 2024 Earnings Call |
2024-05-09 04:02 pm | Q1 2024 Earnings Release |
2024-04-10 03:45 pm | Needham Healthcare Conference - Fireside Chat |
2024-02-22 04:30 pm | Q4 2023 Earnings Call |
2024-02-22 04:09 pm | Q4 2023 Earnings Release |
2023-11-28 04:00 pm | Piper Sandler Healthcare Conference - Fireside Chat |
2023-11-14 04:30 am | Jefferies London Healthcare Conference - Fireside Chat |
2023-11-07 04:30 pm | Q3 2023 Earnings Call |
2023-11-07 04:01 pm | Q3 2023 Earnings Release |
2023-09-06 06:30 pm | PAINWeek Conference - Association Between Per Capita Prescribing |
2023-09-06 06:30 pm | PAINWeek Conference - Misuse and Abuse Trends Across COVID-19 |
2023-09-06 06:30 pm | PAINWeek Conference - Use of Causal Framework |
2023-09-06 06:30 pm | PAINWeek Conference - Real-world Impact of Abuse-Deterrent |
2023-09-06 06:30 pm | PAINWeek Conference - Severity of Medical Outcomes of Exposures |
2023-09-06 06:30 pm | PAINWeek Conference - Misuse/Abuse of XTAMPZA |
2023-09-06 06:30 pm | PAINWeek Conference - Prescription Opioid Misuse/Abuse |
2023-09-06 06:30 pm | PAINWeek Conference - Safety and Tolerability of Buprenorphine |
2023-09-06 06:30 pm | PAINWeek Conference - Treatment Characteristics of Chronic Low Back Pain |
2023-09-06 06:30 pm | PAINWeek Conference - Healthcare Cost and Resource |
Annual results
Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 297 296 0.3% | 310 311 -0.33% | 277 331 -16.36% | 464 460 0.96% | 567 565 0.38% | 583 |
EBITDA Million USD | Released Forecast Spread | 7,53 4,78 57.64% | 140 150 -6.85% | 118 165 -28.16% | 266 256 3.87% | 367 366 0.34% | 386 |
EBIT Million USD | Released Forecast Spread | -23,7 -22,3 -6.56% | 56,2 58,0 -3.01% | 17,6 70,5 -74.98% | 33,3 42,2 -21.08% | 167 153 8.91% | 212 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -22,7 -22,7 0.08% | 27,6 32,9 -16.23% | -3,37 48,3 -106.99% | -28,8 -17,9 -61.49% | 75,7 61,4 23.27% | 166 |
Net income Million USD | Released Forecast Spread | -22,7 -23,2 2.09% | 26,8 30,1 -11.05% | 71,5 109 -34.3% | -25,0 -15,3 -63.32% | 48,2 43,2 11.6% | 121 |
EPS USD | Released Forecast Spread | -0,68 -0,71 4.67% | 0,76 0,90 -15.93% | 1,86 2,89 -35.58% | -0,74 -0,64 -15.18% | 1,29 1,10 17.27% | 3,03 |
Announcement Date | 27/02/20 | 25/02/21 | 24/02/22 | 23/02/23 | 22/02/24 | - |
Quarterly results
Fiscal Period | December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 83,8 78,7 6.46% | 124 121 1.92% | 127 124 2.13% | 130 125 3.52% | 145 138 4.65% | 136 138 -2.07% | 137 140 -2.03% | 150 148 1.49% | 145 147 -1.37% | 143 | 145 | 150 | 149 | 145 |
EBITDA Million USD | Released Forecast Spread | 43,5 41,0 6.18% | 71,2 64,9 9.61% | 74,9 68,6 9.1% | 76,4 69,1 10.59% | 87,6 88,9 -1.49% | 85,8 88,5 -3.02% | 89,4 86,7 3.08% | 104 99,6 4.62% | 92,4 93,8 -1.48% | 92,6 | 94,9 | 102 | 97,0 | 98,6 |
EBIT Million USD | Released Forecast Spread | -10,0 11,2 -189.59% | 11,1 19,0 -41.55% | 20,5 21,4 -4.38% | 11,8 20,6 -43.06% | 24,6 34,9 -29.48% | 35,6 30,6 16.49% | 45,0 41,1 9.41% | 61,7 48,0 28.43% | 49,5 53,7 -7.79% | 50,2 | 53,8 | 59,7 | 53,4 | 54,8 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -15,8 0,37 -4389.39% | -6,65 2,40 -377.19% | 1,43 0,89 60.54% | -7,79 3,21 -342.84% | -17,6 18,2 -196.52% | 17,8 12,2 46.21% | 28,8 23,5 22.34% | 46,7 32,4 44.1% | 36,6 40,1 -8.69% | 36,1 | 43,8 | 51,2 | 45,9 | 48,0 |
Net income Million USD | Released Forecast Spread | -13,1 0,24 -5568.2% | -5,19 1,98 -362.44% | 0,46 1,27 -64.14% | -7,20 2,49 -388.73% | -17,4 9,59 -281.68% | 13,0 11,4 14.15% | 20,6 20,6 -0.06% | 31,9 23,3 36.86% | 27,7 25,1 10.33% | 26,0 | 31,6 | 36,9 | 33,1 | 34,6 |
EPS USD | Released Forecast Spread | -0,39 0,18 -313.7% | -0,15 0,06 -350% | 0,01 -0,14 107.41% | -0,22 -0,15 -51.72% | -0,51 0,31 -262.42% | 0,34 0,29 18.26% | 0,61 0,52 18.06% | 0,82 0,60 36.67% | 0,71 0,64 11.81% | 0,66 | 0,80 | 0,93 | 0,86 | 0,89 |
Announcement Date | 10/05/22 | 04/08/22 | 03/11/22 | 23/02/23 | 04/05/23 | 03/08/23 | 07/11/23 | 22/02/24 | 09/05/24 | - | - | - | - | - |
Past sector events for Collegium Pharmaceutical, Inc.
2024-05-17 08:52 am | J. B. CHEMICALS & PHARMACEUTICALS LIMITED: Q4 2024 Earnings Release |
2024-05-17 04:28 am | GLAXOSMITHKLINE PHARMACEUTICALS LIMITED: Q4 2024 Earnings Release |
2024-05-15 10:05 am | MANKIND PHARMA LIMITED: Q4 2024 Earnings Release |
2024-05-15 01:30 am | DERMAPHARM HOLDING SE: Q1 2024 Earnings Release |
2024-05-15 07:40 am | CRESCO LABS INC.: Q1 2024 Earnings Release |
2024-05-15 03:03 am | GRANULES INDIA LIMITED: Q4 2024 Earnings Release |
2024-05-14 | EISAI CO., LTD.: Q4 2023 Earnings Release |
2024-05-14 05:43 pm | LIQUIDIA CORPORATION: Q1 2024 Earnings Release |
2024-05-14 04:52 am | BORA PHARMACEUTICALS CO., LTD.: Q1 2024 Earnings Release |
2024-05-14 01:30 am | BAYER AG: Q1 2024 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- COLL Stock
- Calendar Collegium Pharmaceutical, Inc.